1. MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability.
- Author
-
Ephraums J, Youkhana J, Raina AS, Schulstad G, Croft K, Mawson A, Kokkinos J, Gonzales-Aloy E, Ignacio RMC, McCarroll JA, Boyer C, Goldstein D, Pajic M, Haghighi KS, Johns A, Gill AJ, Erkan M, Initiative Apgi APCG, Phillips PA, and Sharbeen G
- Subjects
- Animals, Humans, Mice, Cell Line, Tumor, Xenograft Model Antitumor Assays, Cell Proliferation, Apoptosis genetics, RNA, Small Interfering genetics, Oxaliplatin pharmacology, Piperazines pharmacology, Antineoplastic Agents pharmacology, Disease Models, Animal, Phthalazines pharmacology, DNA Repair, Pancreatic Neoplasms genetics, Pancreatic Neoplasms pathology, Pancreatic Neoplasms drug therapy, DNA Glycosylases genetics, DNA Glycosylases metabolism, Gene Knockdown Techniques, Carcinoma, Pancreatic Ductal genetics, Carcinoma, Pancreatic Ductal pathology, DNA Damage
- Abstract
Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year survival rate of just 13 %. Conventional therapies fail due to acquired chemoresistance. We previously identified MutY-Homolog (MYH), a protein that repairs oxidative DNA damage, as a therapeutic target that induces apoptosis in PDAC cells. However, we did not understand the mechanism driving these anti-PDAC effects, nor did we have a means to therapeutically inhibit MYH. In this study, we demonstrated that MYH inhibition induces DNA damage and checkpoint activation in PDAC cells. Using a clinically-relevant PDAC mouse model, we showed that therapeutic MYH-siRNA delivery using Star 3 nanoparticles increased intratumoural PDAC cell death, but did not inhibit tumour growth. Finally, we showed that MYH knockdown in PDAC cells sensitised them to the anti-proliferative and anti-clonogenic effects of oxaliplatin and olaparib. Our findings identify a potential novel therapeutic approach for PDAC that induces a therapeutically exploitable DNA repair vulnerability., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2025. Published by Elsevier Inc.)
- Published
- 2025
- Full Text
- View/download PDF